Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: An open pilot trial
Autore:
Mohr, E; Mendis, T; Hildebrand, K; De Deyn, PP;
Indirizzi:
CroMedica Global Inc, Victoria, BC V8W 3Y7, Canada CroMedica Global Inc Victoria BC Canada V8W 3Y7 toria, BC V8W 3Y7, Canada Univ Ottawa, Ottawa, ON, Canada Univ Ottawa Ottawa ON CanadaUniv Ottawa, Ottawa, ON, Canada Ottawa Civic Hosp, Ottawa, ON K1Y 4E9, Canada Ottawa Civic Hosp Ottawa ONCanada K1Y 4E9 sp, Ottawa, ON K1Y 4E9, Canada Univ Antwerp, Middelheim Hosp, B-2020 Antwerp, Belgium Univ Antwerp Antwerp Belgium B-2020 elheim Hosp, B-2020 Antwerp, Belgium
Titolo Testata:
MOVEMENT DISORDERS
fascicolo: 6, volume: 15, anno: 2000,
pagine: 1230 - 1237
SICI:
0885-3185(200011)15:6<1230:RITTOD>2.0.ZU;2-C
Fonte:
ISI
Lingua:
ENG
Soggetto:
CHRONIC-SCHIZOPHRENIC PATIENTS; DOUBLE-BLIND; TARDIVE-DYSKINESIA; PARALLEL-GROUP; OPEN-LABEL; CLOZAPINE; HALOPERIDOL; MULTICENTER; ONDANSETRON; ANTAGONIST;
Keywords:
risperidone; Parkinson's disease; psychosis; extrapyramidal symptoms;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
51
Recensione:
Indirizzi per estratti:
Indirizzo: Mohr, E CroMedica Global Inc, 600-730 View St, Victoria, BC V8W 3Y7, Canada CroMedica Global Inc 600-730 View St Victoria BC Canada V8W 3Y7 da
Citazione:
E. Mohr et al., "Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: An open pilot trial", MOVEMENT D, 15(6), 2000, pp. 1230-1237

Abstract

PURPOSE: To evaluate the safety and efficacy of risperidone in patients with Parkinson's disease (PD) who are experiencing significant dopamine-induced psychosis. PATIENTS AND METHODS: Seventeen patients (median age, 72 yrs) participatedin this 12-week, open pilot study receiving 0.5 to 3 mg oral risperidone per day. Maintenance antiparkinsonian medication was continued throughout, although psychotropic medication was discontinued. EFFICACY RESULTS: Risperidone produced a substantial improvement in psychotic symptoms, shown on the mean total positive subscale score on the Positive and Negative Syndrome Scale (PANSS) by a 30% improvement (-3.1 decrease)after 1 week and a 66% improvement (-6.8 decrease) at end point. This improvement was most evident in the items delusions, hallucinatory behavior, and suspiciousness/persecution. Risperidone also achieved significant improvement from baseline in Clinical Global Impression (CGI)-severity and CGI-improvement (p <0.001, Page test). Risperidone treatment did not adversely affect symptoms specific to Parkinson's disease, as assessed by the Unified Parkinson's Disease Rating Scale (UPDRS). SAFETY RESULTS: Sixteen patients reported at least one adverse event, but only two patients withdrew as a result of adverse events. No significant changes or clinically relevant abnormalities were observed in laboratory parameters or vital signs. CONCLUSION: Short-term use of risperidone (mean dosage, 1.1 mg per day) improves the psychopathology of patients with PD who have dopamine-induced psychosis without adversely affecting the symptoms of PD. Higher doses and longterm use were not addressed in this study and may be precluded by extrapyramidal side effects.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/02/20 alle ore 06:17:56